Biolyst › RVMDRevolution Medicines, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 15 upcoming events on record.
Cash runway is approximately 33.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Upcoming catalysts
Date Event Type Phase
November 4, 2026 est.
Next quarterly earnings (projected) Earnings
—
December 31, 2026
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors Trial Milestone
Phase 1
March 31, 2027
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Trial Milestone
Phase 1
May 31, 2027
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Trial Milestone
Phase 1/Phase 2
June 15, 2027
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC Trial Milestone
Phase 1/Phase 2
December 1, 2027
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Trial Milestone
Phase 3
April 15, 2028
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors Trial Milestone
Phase 1
June 15, 2028
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Trial Milestone
Phase 3
September 30, 2028
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Trial Milestone
Phase 1/Phase 2
December 15, 2028
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors Trial Milestone
Phase 1/Phase 2
December 30, 2028
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Trial Milestone
Phase 3
March 15, 2029
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Trial Milestone
Phase 3
May 10, 2029
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Trial Milestone
Phase 3
May 15, 2029
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Trial Milestone
Phase 1/Phase 2
October 15, 2029
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Trial Milestone
Phase 3
Track RVMD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RVMD in the tracker
Recent history
Date Event Type Phase
October 13, 2026
8-K filed: Other event Filing
—
September 1, 2026
8-K filed: Material agreement Corporate
—
August 26, 2026
8-K filed: Other event Filing
—
August 5, 2026
Quarterly results filed (8-K) Earnings
—
June 22, 2026
8-K filed: Leadership change Corporate
—
June 15, 2026
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Trial Milestone
Phase 3
May 6, 2026
Quarterly results filed (8-K) Earnings
—
April 17, 2026
8-K filed: Material agreement, Other event Corporate
—
April 16, 2026
8-K filed: Other event Filing
—
April 13, 2026
8-K filed: Other event Filing
—
February 25, 2026
Quarterly results filed (8-K) Earnings
—
November 5, 2025
Quarterly results filed (8-K) Earnings
—
October 17, 2025
8-K filed: Other event Filing
—
September 10, 2025
8-K filed: Other event Filing
—
August 6, 2025
Quarterly results filed (8-K) Earnings
—
June 24, 2025
8-K filed: Material agreement, Reg FD disclosure Corporate
—
June 18, 2025
8-K filed: Leadership change Corporate
—
May 7, 2025
Quarterly results filed (8-K) Earnings
—
July 3, 2024
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies Trial Milestone
Phase 2
May 6, 2024
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors Trial Milestone
Phase 1
February 8, 2022
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC Trial Milestone
Phase 1/Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.